NASDAQ:IFRX

InflaRx Q2 2026 Earnings Results & Report

InflaRx logo
$1.15 -0.03 (-2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 -0.03 (-2.52%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InflaRx missed analyst earnings expectations in its Q2 2026 results, released August 7, 2026. The company reported EPS of -$0.11 versus the -$0.0666 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET

InflaRx EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.0666
Beat/Miss
Missed by -$0.0434
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

InflaRx Revenue Results

Actual Revenue
N/A
Expected Revenue
$6 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

InflaRx Q2 2026 Earnings FAQ

InflaRx (NASDAQ:IFRX) reported earnings of -$0.11 per share for Q2 2026, missing the consensus estimate of -$0.0666. The report was announced on Friday, August 7, 2026.

InflaRx Earnings Headlines

The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
InflaRx (IFRX) AI Stock Analysis
InflaRx Stock Gets Stronger EPS Forecast from HC Wainwright
See More InflaRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email.

About InflaRx

InflaRx (NASDAQ:IFRX) is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage.

The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.

Founded in 2007, InflaRx is headquartered in Jena, Germany, and has operations in the United States. Co-founder Niels C. K. Riedemann has served as the company’s chief executive officer.

View InflaRx Profile